Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Oct;58(4):497–499. doi: 10.1038/bjc.1988.248

Tamoxifen, serum lipoproteins and cardiovascular risk.

P F Bruning 1, J M Bonfrer 1, A A Hart 1, M de Jong-Bakker 1, D Linders 1, J van Loon 1, W J Nooyen 1
PMCID: PMC2246799  PMID: 3207604

Abstract

The influence of tamoxifen on plasma lipids and lipoproteins was monitored in 46 postmenopausal and 8 premenopausal women treated for advanced breast cancer up till 6 months. Total cholesterol (total-C) did not significantly change. However, high density lipoprotein cholesterol (HDL-C) and the HDL-C/total-C ratio rose significantly. Low density lipoprotein cholesterol was significantly decreased. Triglycerides and free fatty acids did not change markedly. The concomitant rise of sex hormone binding globulin and thyroxine binding globulin indicates that the increase of HDL-C with prolonged use of tamoxifen is compatible with an intrinsic oestrogenic effect of tamoxifen on the liver. The increased HDL-C/total-C ratio lends no support to the concern that long-term administration of this anti-oestrogenic drug might lead to an increased cardiovascular risk.

Full text

PDF
497

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bruning P. F., Bonfrer J. M., De Jong-Bakker M., Nooyen W. Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer. J Steroid Biochem. 1984 Sep;21(3):293–298. doi: 10.1016/0022-4731(84)90282-6. [DOI] [PubMed] [Google Scholar]
  2. Brunner D., Weisbort J., Meshulam N., Schwartz S., Gross J., Saltz-Rennert H., Altman S., Loebl K. Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study. Am J Cardiol. 1987 Jun 1;59(15):1271–1276. doi: 10.1016/0002-9149(87)90903-9. [DOI] [PubMed] [Google Scholar]
  3. Burstein M., Scholnick H. R., Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970 Nov;11(6):583–595. [PubMed] [Google Scholar]
  4. Cuzick J., Wang D. Y., Bulbrook R. D. The prevention of breast cancer. Lancet. 1986 Jan 11;1(8472):83–86. doi: 10.1016/s0140-6736(86)90729-4. [DOI] [PubMed] [Google Scholar]
  5. Fex G., Adielsson G., Mattson W. Oestrogen-like effects of tamoxifen on the concentration of proteins in plasma. Acta Endocrinol (Copenh) 1981 May;97(1):109–113. doi: 10.1530/acta.0.0970109. [DOI] [PubMed] [Google Scholar]
  6. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499–502. [PubMed] [Google Scholar]
  7. Fåhraeus L., Larsson-Cohn U., Wallentin L. Lipoproteins during oral and cutaneous administration of oestradiol-17 beta to menopausal women. Acta Endocrinol (Copenh) 1982 Dec;101(4):597–602. doi: 10.1530/acta.0.1010597. [DOI] [PubMed] [Google Scholar]
  8. Gordon T., Kannel W. B., Hjortland M. C., McNamara P. M. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 1978 Aug;89(2):157–161. doi: 10.7326/0003-4819-89-2-157. [DOI] [PubMed] [Google Scholar]
  9. Grundy S. M., Greenland P., Herd A., Huebsch J. A., Jones R. J., Mitchell J. H., Schlant R. C. Cardiovascular and risk factor evaluation of healthy American adults. A statement for physicians by an Ad Hoc Committee appointed by the Steering Committee, American Heart Association. Circulation. 1987 Jun;75(6):1340A–1362A. [PubMed] [Google Scholar]
  10. Krauss R. M. Regulation of high density lipoprotein levels. Med Clin North Am. 1982 Mar;66(2):403–430. doi: 10.1016/s0025-7125(16)31427-4. [DOI] [PubMed] [Google Scholar]
  11. Levy R. I. Cholesterol, lipoproteins, apoproteins, and heart disease: present status and future prospects. Clin Chem. 1981 May;27(5):653–662. [PubMed] [Google Scholar]
  12. Levy R. I. Current status of the cholesterol controversy. Am J Med. 1983 May 23;74(5A):1–4. [PubMed] [Google Scholar]
  13. Lopes-Virella M. F., Stone P., Ellis S., Colwell J. A. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem. 1977 May;23(5):882–884. [PubMed] [Google Scholar]
  14. Mouridsen H., Palshof T., Patterson J., Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat Rev. 1978 Sep;5(3):131–141. doi: 10.1016/s0305-7372(78)80017-6. [DOI] [PubMed] [Google Scholar]
  15. Regouw B. J., Cornelissen P. J., Helder R. A., Spijkers J. B., Weeber Y. M. Specific determination of free fatty acid in plasma. Clin Chim Acta. 1971 Jan;31(1):187–195. doi: 10.1016/0009-8981(71)90377-9. [DOI] [PubMed] [Google Scholar]
  16. Ross R. K., Paganini-Hill A., Mack T. M., Arthur M., Henderson B. E. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet. 1981 Apr 18;1(8225):858–860. doi: 10.1016/s0140-6736(81)92138-3. [DOI] [PubMed] [Google Scholar]
  17. Rössner S., Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis. 1984 Sep;52(3):339–346. doi: 10.1016/0021-9150(84)90064-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES